| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenues | $43K+0.0% | $43K-89.8% | $420K | $0 | $0 | $0 |
| Cost of sales | $609K | — | — | — | — | — |
| Research and development | $848K-87.3% | $6.7M-65.3% | $19.2M-5.5% | $20.3M+31.0% | $15.5M+225.2% | $4.8M |
| General and administrative | $7.7M+43.1% | $5.4M-19.7% | $6.7M-9.0% | $7.4M-1.1% | $7.5M+27.0% | $5.9M |
| Total operating expenses | $9.2M-23.8% | $12.0M-53.4% | $25.9M-6.4% | $27.7M+20.6% | $22.9M+115.7% | $10.6M |
| Operating loss | -$8.4M+29.8% | -$12.0M+52.8% | -$25.5M+8.0% | -$27.7M-20.6% | -$22.9M-115.7% | -$10.6M |
| Foreign exchange losses | $73K+235.2% | -$54K+87.0% | -$414K-277.7% | $233K+429.5% | $44K+100.0% | $22K |
| Interest income | $62K+416.7% | $12K-95.5% | $266K+26.7% | $210K+1212.5% | $16K-61.9% | $42K |
| Gain on deconsolidation of former subsidiary | $4.9M | — | — | — | — | — |
| Other income, net | $354K+580.8% | $52K+4.0% | $50K-96.1% | $1.3M+801.4% | $144K-83.8% | $891K |
| Total other income, net | $5.4M+54260.0% | $10K+110.2% | -$98K-105.6% | $1.7M+753.4% | $204K-78.6% | $955K |
| Loss before taxes | -$3.0M+75.1% | -$12.0M+53.1% | -$25.6M+1.4% | -$25.9M-14.0% | -$22.7M-134.8% | -$9.7M |
| Income tax benefit / (provision) | -$7K-100.9% | $782K-73.9% | $3.0M-36.5% | $4.7M+22.6% | $3.8M+211.2% | $1.2M |
| Net loss | -$3.0M+73.3% | -$11.2M+50.3% | -$22.6M-6.4% | -$21.2M-12.2% | -$18.9M-123.6% | -$8.4M |
| Dividend on convertible exchangeable preferred shares | -$61K | — | -$201K+0.0% | -$201K+0.0% | -$201K+0.0% | -$201K |
| Deemed dividend on warrant exchange | -$11.0M | — | — | — | — | — |
| Net loss applicable to common shareholders | -$14.1M-25.7% | -$11.2M+50.7% | -$22.8M-20.6% | -$18.9M+1.1% | -$19.1M-53.7% | -$12.4M |
| Net loss per share - basic (common shareholders) | -$6450.00+98.7% | -$502460.00-1878255.1% | -$26.75+1.8% | -$27.24+98.7% | -$2140.00+37.4% | -$3420.00 |
| Net loss per share - diluted (common shareholders) | -$6450.00+98.7% | -$502460.00-1878255.1% | -$26.75 | — | -$2140.00+37.4% | -$3420.00 |
| Weighted average common shares outstanding - basic | 2.19B+9692.4% | 22.3M | — | — | 8.93B+145.7% | 3.63B |
| Weighted average common shares outstanding - diluted | 2.19B+9692.4% | 22.3M | — | — | 8.93B+145.7% | 3.63B |
| Product Revenue Fire Safety [Member] | ||||||
| Clinical Trial Supply [Member] | ||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.